论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)患者外周血中ERCC1第118位密码子单核苷酸多态性(SNPs)及与顺铂化疗疗效的相关性。方法:应用荧光偏振(FP)法检测60例NSCLC患者外周血ERCC1118位密码子SNPs,并分析其与顺铂化疗疗效的关系。结果:ERCC1第118位密码子SNPs与NSCLC患者年龄(P=0.25)、性别(P=0.95)、吸烟史(P=0.75)、TNM分期(P=0.45)及组织学类型(P=0.70)无关。GP、NP、DP三种铂类基础化疗方案化疗疗效组间差异无统计学意义,P=0.99。ERCC1第118位密码子C/C基因型组的化疗有效率为48.6%(17/35),而变异型C/T+T/T有效率仅为20%(5/25),χ2=5.27,P=0.02。结论:ERCC1118位密码子SNPs与顺铂化疗疗效相关。
Objective: To investigate the association between the 118th codon SNP of ERCC1 and the efficacy of cisplatin chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods: The SNPs of ERCC1118 codons in peripheral blood of 60 patients with NSCLC were detected by fluorescence polarization (FP) method and their relationship with the efficacy of cisplatin chemotherapy was analyzed. RESULTS: The SNP at codon 118 of ERCC1 was positively correlated with age (P = 0.25), smoking history (P = 0.75), TNM stage (P = 0.45) and histological type (P = 0.70) Nothing to do GP, NP, DP three kinds of platinum based chemotherapy regimen chemotherapy group differences were not statistically significant, P = 0.99. The effective rate of chemotherapy for the 118th codon C / C genotype of ERCC1 was 48.6% (17/35), while the variant C / T + T / T was only 20% (5/25), χ2 = 5.27 , P = 0.02. Conclusion: The SNPs of codon 1118 in ERCC are associated with the efficacy of cisplatin chemotherapy.